Interleukin-6 in rheumatoid arthritis - from the laboratory to the bedside.

  title={Interleukin-6 in rheumatoid arthritis - from the laboratory to the bedside.},
  author={Xiao Lan Liu and Andrew J. Teichtahl and Ian P Wicks},
  journal={Current pharmaceutical design},
  volume={21 17},
Rheumatoid arthritis (RA) is a common and debilitating disease. Expanded therapeutic options, targeting pro-inflammatory cytokines such as tumour necrosis factor (TNF) and interleukin-6 (IL-6), have revolutionised RA treatment. To date, efficacy data shows superiority of IL-6 inhibition over placebo, conventional disease modifying anti-rheumatic drugs such as methotrexate, and TNF inhibition. Moreover, while demonstrating some key differences in the safety profile compared with TNF inhibition… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…